Lessons from “real life experience” of rifaximin use in the management of recurrent hepatic encephalopathy

Figure 3 Cessation probability of persistent hepatic encephalopathy during rifaximin therapy in the subgroup “Prevention of an acute episode on persistent hepatic encephalopathy”, n = 33; Kaplan-Meier method. ¹Censored data correspond to discontinuation of treatment before cessation of hepatic encephalopathy (HE). At the end of follow-up, it corresponded to patients with maintenance of persistent HE.